Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Among authors: robinson s. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. Kottaridis PD, et al. Among authors: robinson s. Blood. 2000 Oct 1;96(7):2419-25. Blood. 2000. PMID: 11001893 Free article. Clinical Trial.
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S. Kottaridis PD, et al. Among authors: robinson s. Cytotherapy. 2001;3(3):197-201. doi: 10.1080/146532401753174025. Cytotherapy. 2001. PMID: 12171726 Clinical Trial.
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N; Lymphoma Working Party of the EBMT. Robinson SP, et al. Haematologica. 2009 Feb;94(2):230-8. doi: 10.3324/haematol.13441. Epub 2008 Dec 9. Haematologica. 2009. PMID: 19066328 Free PMC article.
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S, Vitolo U, Dreyling M, Hermine O; European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Robinson S, et al. Leukemia. 2015 Feb;29(2):464-73. doi: 10.1038/leu.2014.223. Epub 2014 Jul 18. Leukemia. 2015. PMID: 25034148
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X, Nicolas-Virelizier E, Or R, Malladi R, Corby A, Fornecker L, Caballero D, Pohlreich D, Nagler A, Thieblemont C, Finke J, Bachy E, Vincent L, Schroyens W, Schouten H, Dreger P. Robinson SP, et al. Bone Marrow Transplant. 2016 Mar;51(3):365-71. doi: 10.1038/bmt.2015.286. Epub 2015 Nov 30. Bone Marrow Transplant. 2016. PMID: 26618550 Clinical Trial.
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation.
Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, Castagna L, Milpied N, Bacigalupo A, Corradini P, Mohty M, Sanz M, Hausmann A, Montoto S, Robinson S, Boumendil A, Sureda A, Dreger P. Dietrich S, et al. Among authors: robinson s. Leukemia. 2016 Oct;30(10):2086-2089. doi: 10.1038/leu.2016.125. Epub 2016 May 5. Leukemia. 2016. PMID: 27146790 No abstract available.
UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM. Douglas KW, et al. Among authors: robinson s. J Clin Apher. 2018 Feb;33(1):46-59. doi: 10.1002/jca.21563. Epub 2017 Jun 20. J Clin Apher. 2018. PMID: 28631842 Review.
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A. Bazarbachi A, et al. Among authors: robinson s. Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22. Br J Haematol. 2018. PMID: 29468647 Free article. Clinical Trial.
5,121 results